cagrilintide news 2025 Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes In the REDEFINE 1 phase

This makes regular monitoring particularly important for at-risk populations

BPC-157 for women BPC-157 doesn't appear to have different effects based on sex

In severe cases, it is driven by migraine-like neuroinflammation and increased brain sensitivity

Included studies were published over the last 22 years: the oldest was published in 2002 (16), the newest in 2021 [19]

Semaglutides phase 2 trial produced roughly 13% weight loss and clear steatohepatitis resolution yet failed to move fibrosis significantly at 72 weeks a reminder that fibrosis remodeling lags behind fat and inflammation and may require more time or additional mechanisms

I am so grateful to Total Skin and Casey Hoover for their dedication to helping women thrive in perimenopause